ATA News Release 2007

Michael Tuttle, MD, Elected to Board of Directors of the American Thyroid Association

Nov. 16, 2007—R. Michael Tuttle, MD, of New York City, has been elected as a director on the board of the American Thyroid Association (ATA). He will serve a four-year term of office (2007–2011).

Dr. Tuttle is an associate member at Memorial Sloan Kettering Cancer Center and associate professor of medicine at the Joan and Sanford I. Weill Medical College of Cornell University in New York, N.Y. He is an active clinician and researcher specializing in the management of advanced thyroid cancer.

An excellent teacher, Dr. Tuttle travels extensively both within the U.S. and abroad lecturing on the difficult management issues in thyroid cancer. His research projects in radiation-induced thyroid cancer have taken him from Kwajalein Atoll in the Marshall Islands, to the Hanford Nuclear power-plant in Washington State, to regions in Russia that were exposed to fallout from the Chernobyl accident.

Since joining the ATA in 1997, Dr. Tuttle has been a member of the Standards of Care Committee from 1999 to 2005, the ad hoc Web Site Advisory Group since 2003, and chairman of the Clinical Affairs Committee from 2002 to 2005. He currently serves on the Membership Committee and continues to participate in the development and updating of the guidelines on thyroid nodules and thyroid cancer. Other leadership roles he holds include being a member of the National Comprehensive Cancer Network Thyroid Cancer Panel, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee, and Chairman of the Scientific Project Panel of the Chernobyl Tissue Bank.

In Dr. Tuttle’s candidate statement, he expressed his commitment “to continuing and expanding the role of the ATA in the development of the highest quality clinicians, clinical researchers, and basic science researchers. It is through the active, intentional development of the next generation of thyroid researchers and clinicians that the ATA can ensure it will continue to be the leading voice for all things thyroid-related in the years to come.”

For more information, please contact ATA Communications Consultant Jennifer Reising at (703) 300-9248 or jreising@reisingcommunications.com.